Benzinga | Mar 12, 2021 09:02AM EST

Wolfe Research Initiates Coverage On Acceleron Pharma with Outperform Rating, Announces Price Target of $200

Wolfe Research analyst Akash Tewari initiates coverage on Acceleron Pharma (NASDAQ:XLRN) with a Outperform rating and announces Price Target of $200.